Flutemetamol F 18

Flutemetamol F 18

SCHEMBL30668500

CNc1ccc(-c2nc3ccc(O)cc3s2)cc1[18F]

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
APP P05067 18/20 1.00
SULT1A1 P50225 4/20 0.66
MAPT P10636 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Flutemetamol SCHEMBL10032130 1.00 APP (1.00) APPSULT1A1MAPT
Flutemetamol F 18 SCHEMBL29363499 1.00 APP (1.00) APPSULT1A1MAPT
Flutemetamol F 18 SCHEMBL10032147 1.00 APP (1.00) APPSULT1A1MAPT
SCHEMBL5958763 0.87 APP (0.77) APPSULT1A1MAPT
SCHEMBL14788828 0.86 APP (0.75) APPSULT1A1MAPT
SCHEMBL15604181 0.86 APP (0.75) APPMAPT
SCHEMBL13167852 0.85 APP (0.73) APPSULT1A1MAPT
SCHEMBL2061295 0.85 APP (1.00) APPSULT1A1MAPT
SCHEMBL12227066 0.85 APP (1.00) APPSULT1A1MAPT
SCHEMBL13806265 0.84 APP (0.73) APPSULT1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12311036-B2 Metal oxides nanoparticles conjugated with naphthalene derivatives as contrast agents for the detection of beta amyloid plaques by magnetic resonance images CENTRO DE NEUROCIENCIAS DE CUBA (CU) 2025-05-27 US disclosed
CN-113226381-B Naphthalene derivative conjugated metal oxide nanoparticles as contrast agents for detection of beta-amyloid plaques by magnetic resonance imaging 古巴神经科学中心 2023-09-19 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12311036-B2 Metal oxides nanoparticles conjugated with naphthalene derivatives as contrast agents for the detection of beta amyloid plaques by magnetic resonance images L1CAM, NUCB2, TSPO APP 6/4885SULT1A1 2631/4885MAPT 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.